Roche Puts “Mind Towards” Phase III For CETP Inhibitor
Roche is leaning in favor of initiating a Phase III study of its cholesteryl ester transfer protein inhibitor, R1658, after conducting an in-depth analysis of data, evaluating information on Pfizer's failed torcetrapib and consulting experts
You may also be interested in...
Treatment targets for erythropoiesis-stimulating agents in the renal setting need to be accompanied by clinical management information, FDA's Cardiovascular and Renal Drugs and Drug Safety and Risk Management Advisory Committees says
Amgen has the edge as its patent battle against Roche goes to trial this week since the federal judge overseeing the dispute found that Roche's anti-anemia drug Mircera infringes a key Amgen patent
Novartis is now facing a longer delay for its dipeptidyl peptidase-4 agent Galvus (vildagliptin) than previously predicted, since the safety study in patients with renal impairment requested by FDA will take at least six months, not "weeks" as originally suggested